Taken together, our results indicated that increasing FAS expression on tumor cells by pharmacologically inhibiting KDM1A activity could improve the efficacy of L1CAM-specific CAR T cell therapy against neuroblastomas with low or heterogeneous levels of target antigen expression by unleashing antigen-independent killing via the FAS-FASL axis. The gene discussed is FAS; the disease is neoplasm.